“In addition, we expect an approximately 2% revenue headwind due to recent strengthening of the U.S. dollar.”

In context

“installed base grew by high-single-digits and is now more than 60,000 instruments globally. In recent quarters, we've seen healthcare systems and integrated delivery network customers accelerating the placement of new instruments at alternate care sites such as clinics and urgent care centers. This expansion beyond the hospital helps customers improve clinical outcomes and reduce costs by standardizing care across their networks. With the continued expansion of our leading global installed base, the largest test menu on the market and a robust innovation pipeline, Cepheid is well-positioned for sustained long-term growth. Now let's briefly look ahead at expectations for the first quarter and the full year 2025. For the full year 2025, we anticipate core revenue growth of approximately 3%. In addition, we expect an approximately 2% revenue headwind due to recent strengthening of the U.S. dollar. We also expect a full-year adjusted operating profit margin of approximately 28.5%. In the first quarter, we expect core revenue to decline in the low-single-digit percentage range. Additionally, we expect the first quarter adjusted operating profit margin of approximately 26.5%. So to wrap up, we are pleased with our fourth-quarter performance and look forward to building on this momentum as we move into 2025. Our team successfully executed through a dynamic environment to deliver strong financial results, while continuing to invest for the future. Looking ahead, the transformation in our portfolio paired with our organic growth investments has created a lineup of outstanding franchises that are very well-positioned in highly attractive end markets. And we're a better, stronger company t”